So Long, KYTHERA

(RTTNews) - KYTHERA Biopharmaceuticals Inc. (KYTH), one of our stock picks of June 2013, is now set to be acquired by Allergan plc (AGN) in a cash and equity transaction valued at $75 per share, or roughly $2.1 billion.

KYTHERA's lead product KYBELLA, a non-surgical treatment for contouring moderate to severe submental fullness, commonly referred to as double chin, which recently received FDA approval, is said to complement Allergan's existing position in facial aesthetics.

This transaction is anticipated to close in the third quarter of 2015.

KYTH was trading around $22 when we alerted our premium subscribers to the stock on June 6, 2013. Had you bought the stock then, you would have made a gain of more than 235% based on the per share consideration of $75 per share.

Hyperion Therapeutics acquired by Horizon Pharma plc (HZNP) for $46.00 per share, Auspex Pharmaceuticals acquired by Teva Pharmaceutical Industries Ltd. (TEVA) for $101.00 per share, Cubist, acquired by Merck & Co. (MRK) for $102 a share, Idenix, also acquired by Merck for $24.50 a share, and Avanir acquired by Otsuka Pharmaceutical for $17 per share were the other stock picks we alerted our premium subscribers to before the companies were bought out.

Visit Emerging Biostocks for a complete list of our biotech stock picks.